Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY BACKGROUND
Company Background      
Astrazeneca Pharma India Ltd.
Industry : Pharmaceuticals & Drugs House : Astrazeneca Pharma India - MNC
BSE Code 506820
ISIN Demat INE203A01020
Book Value 271.74
NSE Code ASTRAZEN
Dividend Yield % 0.37
Market Cap 162421.25
P/E 198.27
EPS 32.77
Face Value 2  
 
Incorporation Year 11-07 1979  
Registered Office Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road, Bengaluru,
Karnataka-560045 .
ISINNO INE203A01020  
Phone 080 6774 8000  
E-mail comp.secy@astrazeneca.com
URL www.astrazenecaindia.com/india
Industry Pharmaceuticals & Drugs  
Chairman Shilpa Divekar Nirula  
Managing Director Sanjeev Kumar Panchal  
Company Secretary Manasa R  
Listing BSE,NSE  
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA
Publishing of investor charter information | Annexure A – Investor charter of brokers |
Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.